Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 21:12:720109.
doi: 10.3389/fimmu.2021.720109. eCollection 2021.

Monocytes and Macrophages in COVID-19

Affiliations
Review

Monocytes and Macrophages in COVID-19

Rainer Knoll et al. Front Immunol. .

Abstract

COVID-19 is a contagious viral disease caused by SARS-CoV-2 that led to an ongoing pandemic with massive global health and socioeconomic consequences. The disease is characterized primarily, but not exclusively, by respiratory clinical manifestations ranging from mild common cold symptoms, including cough and fever, to severe respiratory distress and multi-organ failure. Macrophages, a heterogeneous group of yolk-sac derived, tissue-resident mononuclear phagocytes of complex ontogeny present in all mammalian organs, play critical roles in developmental, homeostatic and host defense processes with tissue-dependent plasticity. In case of infection, they are responsible for early pathogen recognition, initiation and resolution of inflammation, as well as repair of tissue damage. Monocytes, bone-marrow derived blood-resident phagocytes, are recruited under pathological conditions such as viral infections to the affected tissue to defend the organism against invading pathogens and to aid in efficient resolution of inflammation. Given their pivotal function in host defense and the potential danger posed by their dysregulated hyperinflammation, understanding monocyte and macrophage phenotypes in COVID-19 is key for tackling the disease's pathological mechanisms. Here, we outline current knowledge on monocytes and macrophages in homeostasis and viral infections and summarize concepts and key findings on their role in COVID-19. While monocytes in the blood of patients with moderate COVID-19 present with an inflammatory, interferon-stimulated gene (ISG)-driven phenotype, cellular dysfunction epitomized by loss of HLA-DR expression and induction of S100 alarmin expression is their dominant feature in severe disease. Pulmonary macrophages in COVID-19 derived from infiltrating inflammatory monocytes are in a hyperactivated state resulting in a detrimental loop of pro-inflammatory cytokine release and recruitment of cytotoxic effector cells thereby exacerbating tissue damage at the site of infection.

Keywords: COVID-19; SARS-CoV-2; alveolar macrophage; hyperinflammation; macrophage; monocytes; scRNA-seq; viral infection.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Monocytes and Macrophages in COVID-19. Graphical overview of the compositional and molecular alterations in monocyte and alveolar macrophage populations in COVID-19 created with BioRender.com. Distinct monocyte and macrophage phenotypes were identified in the peripheral blood of patients with severe COVID-19 including immature cells indicating emergency myelopoiesis, dysfunctional HLA-DRlo classical monocytes and complement gene expressing non-classical monocytes. These cells are attracted to the lung by pro-inflammatory chemokines resulting in a continuous accumulation of hyperactivated MNPs producing more pro-inflammatory mediators recruiting more inflammatory cells, including cytotoxic T cells and neutrophils, thus further exacerbating inflammation and tissue damage. SARS-CoV-2 infected macrophages in the lung may act as trojan horses propagating SARS-CoV-2 infection and spreading hyperinflammation across the lung.

Similar articles

Cited by

References

    1. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med (2020) 383:2451–60. 10.1056/NEJMcp2009575 - DOI - PubMed
    1. Gandhi RT, Lynch JB, del Rio C. Mild or Moderate Covid-19. N Engl J Med (2020) 383:1757–66. 10.1056/NEJMcp2009249 - DOI - PubMed
    1. Kim D, Lee JY, Yang JS, Kim JW, Kim VN, Chang H. The Architecture of SARS-CoV-2 Transcriptome. Cell (2020) 181:914–21.e10. 10.1016/j.cell.2020.04.011 - DOI - PMC - PubMed
    1. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. . A New Coronavirus Associated With Human Respiratory Disease in China. Nature (2020) 579:265–9. 10.1038/s41586-020-2008-3 - DOI - PMC - PubMed
    1. Zhang YZ. Holmes EC. A Genomic Perspective on the Origin and Emergence of SARS-CoV-2. Cell (2020) 181:223–7. 10.1016/j.cell.2020.03.035 - DOI - PMC - PubMed

Publication types

Substances